This post has been archived and contains information that may be out of date.
The Food and Drug Administration (FDA) has authorized the emergency use of the monoclonal antibody bebtelovimab for the treatment of mild-to-moderate COVID-19 in adult and pediatric patients, and the Centers for Medicare & Medicaid Services (CMS) has created new billing codes for the treatment.
This content is restricted to members.
